Vitamin D3-24-hydroxylase (CYP24) as a potential target for intervention with diabetic and nondiabetic nephropathy.
Weiher
Hans
H
GTX Pharmaceuticals, Griöbenzell, Germany. hans.weiher@fh-bonn-rhein-sieg.de
Zwacka
Ralf M
RM
D000818:Animals; D003928:Diabetic Nephropathies / Q000235:genetics / Q000378:metabolism*; D005260:Female; D020869:Gene Expression Profiling; D005921:Glomerulonephritis / Q000235:genetics / Q000378:metabolism*; D007668:Kidney / Q000378:metabolism*; D008565:Membrane Proteins / Q000235:genetics*; D051379:Mice; D016688:Mice, Inbred NOD; D018345:Mice, Knockout
D008565:Membrane Proteins; C065292:Mpv17 protein, mouse